PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10378768-13 1999 These findings suggested that an unknown transporter distinct from P-gp, MRP or cMOAT is expressed in KCP-4 cells and transports CPT-11 and SN-38. Irinotecan 129-135 ATP binding cassette subfamily C member 1 Homo sapiens 73-76 10220571-0 1999 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Irinotecan 24-30 ATP binding cassette subfamily C member 1 Homo sapiens 48-76 10220571-0 1999 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Irinotecan 24-30 ATP binding cassette subfamily C member 1 Homo sapiens 78-81 10220571-0 1999 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Irinotecan 35-40 ATP binding cassette subfamily C member 1 Homo sapiens 48-76 10220571-0 1999 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Irinotecan 35-40 ATP binding cassette subfamily C member 1 Homo sapiens 78-81 10220571-3 1999 To see whether MRP is involved in CPT-11 and SN-38 resistance, MRP cDNA was transfected into KB-3-1 cells. Irinotecan 45-50 ATP binding cassette subfamily C member 1 Homo sapiens 15-18 10220571-4 1999 The transfectant, KB/MRP, which overexpressed MRP, was resistant to both CPT-11 and SN-38. Irinotecan 73-79 ATP binding cassette subfamily C member 1 Homo sapiens 21-24 10220571-4 1999 The transfectant, KB/MRP, which overexpressed MRP, was resistant to both CPT-11 and SN-38. Irinotecan 73-79 ATP binding cassette subfamily C member 1 Homo sapiens 46-49 10220571-4 1999 The transfectant, KB/MRP, which overexpressed MRP, was resistant to both CPT-11 and SN-38. Irinotecan 84-89 ATP binding cassette subfamily C member 1 Homo sapiens 21-24 10220571-4 1999 The transfectant, KB/MRP, which overexpressed MRP, was resistant to both CPT-11 and SN-38. Irinotecan 84-89 ATP binding cassette subfamily C member 1 Homo sapiens 46-49 10220571-6 1999 The accumulation of both CPT-11 and SN-38 in C-A120 and KB/MRP cells was lower than that in KB-3-1 cells. Irinotecan 25-31 ATP binding cassette subfamily C member 1 Homo sapiens 59-62 10220571-6 1999 The accumulation of both CPT-11 and SN-38 in C-A120 and KB/MRP cells was lower than that in KB-3-1 cells. Irinotecan 36-41 ATP binding cassette subfamily C member 1 Homo sapiens 59-62 10220571-7 1999 The treatment with 10 microM PAK-104P increased the accumulation of CPT-11 and SN-38 in C-A120 and KB/MRP cells to a level similar to that found in KB-3-1 cells. Irinotecan 68-74 ATP binding cassette subfamily C member 1 Homo sapiens 102-105 10220571-7 1999 The treatment with 10 microM PAK-104P increased the accumulation of CPT-11 and SN-38 in C-A120 and KB/MRP cells to a level similar to that found in KB-3-1 cells. Irinotecan 79-84 ATP binding cassette subfamily C member 1 Homo sapiens 102-105 10220571-8 1999 The ATP-dependent efflux of CPT-11 and SN-38 from C-A120 and KB/MRP cells was inhibited by PAK-104P. Irinotecan 28-34 ATP binding cassette subfamily C member 1 Homo sapiens 64-67 10220571-8 1999 The ATP-dependent efflux of CPT-11 and SN-38 from C-A120 and KB/MRP cells was inhibited by PAK-104P. Irinotecan 39-44 ATP binding cassette subfamily C member 1 Homo sapiens 64-67 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 43-49 ATP binding cassette subfamily C member 1 Homo sapiens 28-31 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 43-49 ATP binding cassette subfamily C member 1 Homo sapiens 199-202 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 54-59 ATP binding cassette subfamily C member 1 Homo sapiens 28-31 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 54-59 ATP binding cassette subfamily C member 1 Homo sapiens 199-202 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 93-99 ATP binding cassette subfamily C member 1 Homo sapiens 28-31 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 104-109 ATP binding cassette subfamily C member 1 Homo sapiens 28-31 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 93-99 ATP binding cassette subfamily C member 1 Homo sapiens 28-31 10220571-11 1999 These findings suggest that MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11 and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38 in tumors that overexpress MRP. Irinotecan 104-109 ATP binding cassette subfamily C member 1 Homo sapiens 28-31 10378768-13 1999 These findings suggested that an unknown transporter distinct from P-gp, MRP or cMOAT is expressed in KCP-4 cells and transports CPT-11 and SN-38. Irinotecan 140-145 ATP binding cassette subfamily C member 1 Homo sapiens 73-76 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Irinotecan 51-61 ATP binding cassette subfamily C member 1 Homo sapiens 275-280 30925062-5 2019 In addition, the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daunorubicin and SN-38, respectively, in concentration ranges that qualified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature. Irinotecan 124-129 ATP binding cassette subfamily C member 1 Homo sapiens 217-222 29499902-0 2018 Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. Irinotecan 52-62 ATP binding cassette subfamily C member 1 Homo sapiens 30-34 21529984-6 2011 The expression status of Klotho, and of the ATP-binding cassette (ABC) transporters MRP1, MDR and breast cancer resistant protein (BCRP), which can cause resistance to anticancer drugs, including irinotecan, was assessed by immunohistochemical analysis in resected surgical specimens of patients with early-stage SCLC. Irinotecan 196-206 ATP binding cassette subfamily C member 1 Homo sapiens 84-88 27845419-4 2018 rs6498588 (ABCC1) and rs12720066 (ABCB1) were associated with increased SN-38 exposure, and rs17501331 (ABCC1) and rs12720066 were associated with lower absolute neutrophil count nadir. Irinotecan 72-77 ATP binding cassette subfamily C member 1 Homo sapiens 11-16 27845419-7 2018 These results suggest that genetic variation in ABCC1 and ABCB1 may contribute to irinotecan-induced neutropenia by altering expression of transporters involved in irinotecan metabolite disposition. Irinotecan 82-92 ATP binding cassette subfamily C member 1 Homo sapiens 48-53 27845419-7 2018 These results suggest that genetic variation in ABCC1 and ABCB1 may contribute to irinotecan-induced neutropenia by altering expression of transporters involved in irinotecan metabolite disposition. Irinotecan 164-174 ATP binding cassette subfamily C member 1 Homo sapiens 48-53 26352872-4 2015 MATERIALS AND METHODS: In this study, we aimed to discover toxicity-associated markers in seven transporter genes participating in irinotecan pharmacokinetics involving the ABC transporter genes ABCB1, ABCC1, ABCC2, ABCC5, ABCG1, and ABCG2 and the solute carrier organic anion transporter gene SLCO1B1 and using a haplotype-tagging single-nucleotide polymorphisms (n=210 htSNPs) strategy. Irinotecan 131-141 ATP binding cassette subfamily C member 1 Homo sapiens 202-207 21787264-6 2011 However, the complex pharmacokinetics of irinotecan and the involvement of several enzymes other than UGT (i.e., carboxyl estherases, CYP450 isoforms), and transmembrane transporters (ABCB1, ABCC1, ABCG2, SLCO1B1) make difficult the identification of patients with an optimal sensitivity and specificity, and a large part of variability among patients still remains unexplained. Irinotecan 41-51 ATP binding cassette subfamily C member 1 Homo sapiens 191-196 29016119-5 2017 The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells. Irinotecan 170-175 ATP binding cassette subfamily C member 1 Homo sapiens 211-215 26950035-0 2016 MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. Irinotecan 46-56 ATP binding cassette subfamily C member 1 Homo sapiens 0-4 26950035-3 2016 Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds. Irinotecan 117-127 ATP binding cassette subfamily C member 1 Homo sapiens 0-41 26950035-3 2016 Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds. Irinotecan 117-127 ATP binding cassette subfamily C member 1 Homo sapiens 43-47 26950035-7 2016 Among patients treated with irinotecan-based chemotherapy, 4 out of 19 cases with MRP1 positive CTCs showed a worse progression free survival (PFS) in comparison to those with MRP1 negative CTCs (2.1 months vs. 9.1 months; p = 0.003). Irinotecan 28-38 ATP binding cassette subfamily C member 1 Homo sapiens 82-86 26950035-7 2016 Among patients treated with irinotecan-based chemotherapy, 4 out of 19 cases with MRP1 positive CTCs showed a worse progression free survival (PFS) in comparison to those with MRP1 negative CTCs (2.1 months vs. 9.1 months; p = 0.003). Irinotecan 28-38 ATP binding cassette subfamily C member 1 Homo sapiens 176-180 26950035-10 2016 Our results show MRP1 as a potential biomarker of resistance to treatment with irinotecan when found in CTCs from mCRC patients. Irinotecan 79-89 ATP binding cassette subfamily C member 1 Homo sapiens 17-21 20726333-8 2010 An immunoblotting analysis followed by densitometry revealed that the combination of IL-1beta plus CPT-11 added to the cocultures led to a decrease in HSPs and MRP levels. Irinotecan 99-105 ATP binding cassette subfamily C member 1 Homo sapiens 160-163 19349540-7 2009 Almost 30% of the variability in SN-38 (the active metabolite of CPT-11) AUC is explained by ABCC1 1684T>C, ABCB1 IVS9 -44A>G, and UGT1A1*93 (P = .004). Irinotecan 33-38 ATP binding cassette subfamily C member 1 Homo sapiens 93-98 20093746-12 2009 rhTGF-beta1 and/or CPT-11 may potentate resistance to chemotherapy by increasing HSP and MRP expression but, on the other hand, they may limit tumour cell spread by decreasing the level of some soluble mediators of inflammation (IL-6 and NO). Irinotecan 19-25 ATP binding cassette subfamily C member 1 Homo sapiens 89-92 19349540-7 2009 Almost 30% of the variability in SN-38 (the active metabolite of CPT-11) AUC is explained by ABCC1 1684T>C, ABCB1 IVS9 -44A>G, and UGT1A1*93 (P = .004). Irinotecan 65-71 ATP binding cassette subfamily C member 1 Homo sapiens 93-98 16508919-5 2006 Many enzymes are involved in controlling the disposition of irinotecan, including the cellular target (TOP1), metabolism enzymes (CES2, UGT1A1, CYP3A4, CYP3A5), and cellular transporters of the anti-cancer agent (ABCB1, ABCC1, ABCC2, ABCC3, ABCC5, ABCG2). Irinotecan 60-70 ATP binding cassette subfamily C member 1 Homo sapiens 220-225 18690847-3 2008 The aim of the study was to investigate the induction by celecoxib of some multidrug resistance proteins, MRP1, MRP2, MRP4 and MRP5, involved in the transport of irinotecan and 5-FU. Irinotecan 162-172 ATP binding cassette subfamily C member 1 Homo sapiens 106-110 15897249-8 2005 Methylselenocysteine/CPT-11 treatment, compared with CPT-11 alone, resulted in a significant decrease in levels of ABCC1 and DRG1 in FaDu tumors and an increase in levels of CYP3A5 and TNFSF6 in A253 tumors. Irinotecan 21-27 ATP binding cassette subfamily C member 1 Homo sapiens 115-120 15897249-10 2005 In conclusion, the significant increase in the cure rate after methylselenocysteine/CPT-11 could be related to increased drug delivery into both tumors (CES1), reduced resistance to SN-38 (ABCC1 and DRG1) in FaDu, and induced Fas ligand apoptosis (TNFSF6) in A253. Irinotecan 84-90 ATP binding cassette subfamily C member 1 Homo sapiens 189-194 15897249-10 2005 In conclusion, the significant increase in the cure rate after methylselenocysteine/CPT-11 could be related to increased drug delivery into both tumors (CES1), reduced resistance to SN-38 (ABCC1 and DRG1) in FaDu, and induced Fas ligand apoptosis (TNFSF6) in A253. Irinotecan 182-187 ATP binding cassette subfamily C member 1 Homo sapiens 189-194 16132345-3 2005 P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan. Irinotecan 126-132 ATP binding cassette subfamily C member 1 Homo sapiens 50-54 16132345-3 2005 P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan. Irinotecan 134-144 ATP binding cassette subfamily C member 1 Homo sapiens 50-54 16132345-3 2005 P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan. Irinotecan 147-152 ATP binding cassette subfamily C member 1 Homo sapiens 50-54 16132345-3 2005 P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan. Irinotecan 179-185 ATP binding cassette subfamily C member 1 Homo sapiens 50-54